Gibson James R II sold $2.1M of PACB

Gibson James R II (See Remarks) sold 661,815 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) at $3.11 ($2.06M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gibson James R II
Published Oct 8, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACB
Neutral
medium confidence
Mentioned
$PACB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACBNeutralLow
01

Why it matters

The disclosed sale is planned via a Rule 10b5-1 arrangement, which generally lowers the informational content relative to non-10b5-1 discretionary selling.

02

Market read

Traders may monitor PACB for any follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing by itself.

03

What to watch

Because the transaction is explicitly under a pre-arranged 10b5-1 plan, traders may discount it; any real impact would more likely come from concurrent company-specific catalysts not mentioned here.

Relevance 5/10Novelty 6/10Timing: filed after-hours on 2026-10-08, covering a sale dated 2026-10-06

Background

The article is an SEC Form 4 insider transaction disclosure for Pacific Biosciences of California, Inc. (PACB).

Company-level read

Ticker impact

$PACBNeutralMedium confidence
Context

PACB Form 4 shows officer Gibson James R II sold 661,815 shares for about $2.06M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited downside pressure, with the market treating the sale as planned rather than a fresh negative signal.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the presence of a pre-arranged 10b5-1 plan usually reduces interpretive weight versus discretionary selling.

Market effects

Minimal spillover to biotech peers; this is a single-company insider transaction.

None.

None.

Counterpoint

The sale could be interpreted as a signal of liquidity needs or diversification rather than any negative view, so price impact may be negligible.

Key entities

  • PACB

    Pacific Biosciences of California, Inc., the company whose insider transaction is disclosed.

  • Gibson James R II

    Officer of PACB who sold 661,815 shares on 2026-10-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACBMed

Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue

Pacific Biosciences (PACB) reported Q3 2026 revenue growth of 6% YoY to $40.6M, with consumables revenue down 2% YoY. Non-GAAP gross margin fell to 36% from 42% due to higher costs. Americas and Asia Pacific revenues declined, while EMEA grew 30%. Cash burn was $32.8M, with Q4 expected to decrease. The company narrowed full-year revenue guidance to $155M-$160M and expects cash flow breakeven in 2028.

$PACBHighAI 8/10

What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences (PACB) reported Q3 earnings, with Revio consumables pull-through at $204,000 per system. Instrument revenue rose to $13.2M, with 15 Revio and 35 Vega systems sold. Clinical business grew over 20% YoY, now exceeding 20% of total business. Non-GAAP net loss narrowed to $32.8M, with cash at $199.4M. The company maintained its 2026 outlook and expects cash flow breakeven in 2028.

$PACBMed

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): PacBio Announces Third Quarter 2026 Financial Results

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights • Delivered total revenue of $40

$PACBMed

Why PacBio (PACB) Stock Is Trading Up Today

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.